Alkermes plc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Alkermes announced on September 16, 2026, the appointment of Anne C. Whitaker as an independent director to its Board. Whitaker is a seasoned biopharmaceutical executive with CEO experience at Aerami Therapeutics, Novoclem Therapeutics, and Synta Pharmaceuticals, plus prior leadership roles at Sanofi, GSK, and Bausch Health. She currently serves on boards of public companies Basilea Pharmaceutica and ICON plc, and multiple private life sciences firms.
Why this rating
Routine board appointment; no financial impact stated. Standard governance action immaterial to $4.7B market-cap company operations or strategy.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.